ReviewWorld journal of hepatology2022
Therapies for non-alcoholic fatty liver disease: A 2022 update.
Review in World journal of hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Anthocyanin-Rich Extracts from Bilberries and Blackcurrants in Human Health: A Narrative Review of Their Anti-Inflammatory and Antioxidant Effects.Journal of clinical medicine · 2026Review
- Eating behaviors and liver health in metabolic dysfunction-associated fatty liver disease: the serial mediating roles of Mediterranean diet adherence and adiposity.Frontiers in nutrition · 2026Article
- Bridging the Knowledge Gap: A National Survey on MASLD Awareness and Management Barriers in the Saudi Population.Healthcare (Basel, Switzerland) · 2025Article
- Exploratory analysis of the association between dietary niacin intakes and nonalcoholic fatty liver disease among US adults: 1999-2018 data analysis from the National Health and Nutrition Examination Survey (NHANES).Journal of clinical biochemistry and nutrition · 2025Article
- Impact of Pathological Grades of Metabolic Dysfunction-Associated Steatotic Liver Disease on Weight Loss Following Laparoscopic Sleeve Gastrectomy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Decoding the Knacks of Ellagitannin Lead Compounds to Treat Nonalcoholic Fatty Liver Disease using Computer-aided Drug Designing.Current computer-aided drug design · 2025Article
- Telemedicine as an Option for Monitoring Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Patients Facing the COVID-19 Pandemic: A Systematic Review and Meta-Analysis.Journal of personalized medicine · 2024Review
- Oral Insulin Alleviates Liver Fibrosis and Reduces Liver Steatosis in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes: Results of Phase II Randomized, Placebo-controlled Feasibility Clinical Trial.Gastro hep advances · 2024Article
- Article
- Research progress on the therapeutic effects of polysaccharides on non-alcoholic fatty liver diseases.Frontiers in nutrition · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing and lifestyle interventions to treat this disease by addressing the underlying metabolic syndrome are often limited. Many pharmacological interventions are being studied to slow or even reverse NAFLD progression. This review for hepatologists aims to provide an updated understanding of the pathogenesis of NAFLD, current recommended therapies, and the most promising treatment options that are currently under development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.